This article by Jill Ettinger was originally published on Psychedelic Spotlight, and appears here with permission.
New research out of Australia points to the benefits of ketamine therapy in reducing suicidal thoughts. The findings are published in the journal Translational Psychiatry.
According to the study, two-thirds of the patients who participated more than 60 percent experienced a significant reduction in suicidal thoughts after taking oral doses of ketamine for six weeks.
Participants were defined as suffering from chronic suicidality ongoing thoughts of suicide.
“On average, patients experienced a significant reduction in suicide ideation, from a high level before the trial to below the clinical threshold by week six of the trial,” lead researcher Adem Can of the University of Sunshine Coast said in a statement. “In medicine, this response rate is significant, particularly given it was experienced by patients with chronic suicidality, which can be difficult
This article by Jill Ettinger was originally published on Psychedelic Spotlight, and appears here with permission.
While most of us are eager to put 2020 behind us, a few industries had banner years during lockdown. Pizza delivery and Zoom subscriptions may top the list but it was also a huge year for psychedelics. From major legislative victories to a record number of companies going public to big-name celeb endorsements, 2020 was, to say the least, one heck of a trip.
Credit in part, at least, can go to the pandemic itself. As we all hunkered down and sheltered at home trying to wrap our heads around the crisis, for some, it became an eye-opener. Many were nudged toward inner reflection and an open mind to new possibilities. A record number of Americans hit the polls this election bringing two key victories for psychedelics as a result. The nation’s capital voted to decriminalize psychedelics and Oregon voted to decriminalize psychedelics and legalize therapeutic psilocybin